[Treatment of pulmonary hypertension in COPD: is there hope for the better?].
The aim of this study is to prove for a well tolerated medication (clinical and financial) a supplementary effect in improvement prognosis of patients with pulmonary hypertension secondary to COPD, already treated with classical pneumology drugs. Three pts. groups were selected: the first received only classical pneumology treatment, the second with supplementary therapy by IECA and Ca-blockers, the third with supplementary therapy with IECA and nebivolol; the follow-up protocol included clinical and paraclinical status (blood gases, spirometry, ECG, echocardiography, 6 minute walk test) over 3 months. Clinical and paraclinical evolution of the pts. in group 2 and group 3 was significantly better that in pts from group 1. We conclude that addition of IECA + Ca-blocker/IECA + nebivolol therapy at classical pneumology therapy result in a better evolution in pts. with pulmonary hypertension secondary to COPD.
Tesloianu
Anda
A
Spitalul Clinic Pneumologie Iaşi.
Eşanu
Valentina
V
Mihăescu
Tr
T
Spiridon
Marilena
M
Tesloianu
D
D
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001578:Benzopyrans / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D000068577:Nebivolol; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001578:Benzopyrans; D002121:Calcium Channel Blockers; D004983:Ethanolamines; D000068577:Nebivolol